Thanks BooDog! I find it interesting (odd) that CTIX write-up is focused on Brilacidin and Polymedix compounds. Guess Leo is trying to get the word out to investors as the antibiotic field seems to be getting the most attention lately? Maybe he can get a quick partnership or something? I don't think Kevetrin should be taking a "back seat" to anything . . .
